Amibegron (SR-58,611A) is a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the Central Nervous System, and has antidepressant and anxiolytic effects.

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.






This page contains text from Wikipedia, the Free Encyclopedia - http://en.wikipedia.org/wiki/Amibegron

This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.